Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing)

N/A

Report date: 2025/09/26 20:00:51

Base Information

Drug NameAnti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphomaLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesThe Southwest Hospital of AMU

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Southwest Hospital of AMU

Active IndicationsN/A

Inactive IndicationsLymphoma, Large B-Cell, DiffuseLymphomaLeukemia

Other Information

ATC CodeN/A